pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TARSTarsus Pharmaceuticals, Inc.

$TARS73.01-6.00%
Irvine, CA, USupdated 30m ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 2Marketed: 1
2Phase 21Marketed
Marketed
lotilaner
Demodex Blepharitis
Phase 2
TP-04
Ocular Rosacea
Phase 2
TP-05
Lyme Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$TARS73.01-6.00%
17d ago
Tarsus Pharmaceuticals, Inc. earnings
Tarsus Pharmaceuticals, Inc.
→
view all catalysts →

Active trials

  • phase2A Study to Evaluate the Efficacy and Safety of TP-06 for PCEDrecruitingn=32
  • phase2A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposureactive not recruitingn=722
  • phase2Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)enrolling by invitationn=155
  • phase2Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGDcompletedn=39
  • phase4Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearerscompletedn=145
  • phase2A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05completedn=30
  • phase1A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjectscompletedn=24
  • phase2Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodexactive not recruitingn=36
🐶 Hiring Signal
No open roles indexed yet — view Tarsus Pharmaceuticals, Inc. jobs →

News

  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 10d ago
  • M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
    After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.
    biospace · 1mo ago
  • Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
    Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”
    biopharma_dive · 3mo ago
  • ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
    biopharma_dive · 4mo ago
identifiers
ticker
$TARS
SEC CIK
0001819790
country
US
source
sec_tickers
top tags
Dermatology1Infectious Disease1Ophthalmology1
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?